Evommune Inc EVMN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
-
Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
-
Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
-
Evommune Reports Second Quarter 2026 Financial Results and Provides Business Highlights
-
Evommune Initiates Phase 2b Clinical Trial of MRGPRX2 Inhibitor EVO756 in Migraine Prophylaxis
Trading Information
- Previous Close Price
- $5.93
- Day Range
- $5.09–6.00
- 52-Week Range
- $5.09–33.20
- Bid/Ask
- $4.98 / $6.29
- Shares Outstanding
- 36.29M
- Market Cap
- $187.63M
- Volume/Avg
- 986,709 / 686,341
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 3.61
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 48
- Website
- https://www.evommune.com
Valuation
|
Metric
|
EVMN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.77 |
Price/Sales | 3.61 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
EVMN
|
|---|---|
Quick Ratio | 11.48 |
Current Ratio | 11.68 |
Interest Coverage | — |
Quick Ratio
EVMN
Profitability
|
Metric
|
EVMN
|
|---|---|
Return on Assets (Normalized) | −39.73% |
Return on Equity (Normalized) | −94.45% |
Return on Invested Capital (Normalized) | −98.57% |
Return on Assets
EVMN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|!FZ%z? | LOCK|Fx&%> | $127B | |||
| Moderna Inc
MRNA
| LOCK|%lh>^X | LOCK|bP | $87B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|^y$#TW | LOCK|H?cM$ | $81B | |||
| argenx SE ADR
ARGX
| LOCK|zp!BG! | LOCK|<l | $51B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|?dZP!yN | LOCK|&X | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|rdhgz@y | LOCK|@dN% | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&Tm^FQ% | LOCK|?s@J | $27B | |||
| Incyte Corp
INCY
| LOCK|Y>@&^l | LOCK|>C# | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|nT!DV#s | LOCK|BW | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|^$Jd@!T | LOCK|Qz | $14B |
United States